MSInsight Raises €1.6M in Seed Funding
Summary
Backers included Calyseed, with participation from Plateau de Saclay Business Angels, Yes Invest, Capital Cell, and banking partners such as bpifrance. The company intends to use the funds to finalize its technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical validation necessary for its CE-IVD marking as an in vitro diagnostic medical device. Led by Arnaud Cutivet, PhD, president and co-founder, MSInsight offers diagnostic solutions to identify crucial information in patients’ DNA to predict the success of treatments. It has developed MSIcare, a medical device software integrating bioinformatics algorithms and artificial intelligence models derived from its expertise to interpret the patient’s genomic data and identify information of interest. The solution proposed by MSInsight makes it possible to significantly improve the detection of the MSI biomarker in different contexts and to democratize its access thanks to an optimized interpretation interface of the results.